This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
“Not only does the location has offer competitive costs [but it has] proximity to our existing European-based production and commercial operations.” Full operations is provisionally planned for late 2026. This brings the total new investment commitment to the network in the past few years to €250 million.
Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.
Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. Lines are blurring between payers and providers More and more, large integrated delivery networks and national payers are battling each other for greater control over patient costs and outcomes.
Networking, building a relationship, and not having it need to go somewhere. If it’s 2026 and you’re reading this, this happened in 2023. A big lesson for me was to talk to people and know that it might not go anywhere, and that’s okay. However, maybe you are in a position. I know I dated this episode.
That way, they can continue to grow membership and thrive against the competition. In 2026, payers will need to send prior authorization decisions within 72 hours for urgent requests and seven business days for standard requests. These changes are designed to make care easier to access for enrollees.
Retaining loyal members requires a smart, tailored approach to stay competitive." And so networks might be squeezed by this. However, I've heard there are some rumors out there that there are some plans that will be entering the marketplace for 2025 to offer 2026 benefits. And yet, you know, things never seemed to stay the same.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content